Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $323

Benzinga · 1d ago
Canaccord Genuity analyst Whitney Ijem maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $429 to $323.